Lymphatic Filariasis Mass Drug Administration
On this page
Direct answer
Once a year, in every filariasis-endemic district, nearly everyone swallows preventive medicine on a single designated day — that is mass drug administration (MDA), the core strategy of India's lymphatic filariasis elimination effort under the Global Programme to Eliminate Lymphatic Filariasis. The original regimen was diethylcarbamazine citrate (6 mg per kg) plus albendazole (400 mg) annually; following WHO's 2017 recommendation, India moved district-by-district to the triple-drug IDA regimen adding ivermectin (200 micrograms per kg), which clears microfilariae faster and may shorten the number of rounds needed. India began MDA in 2004 across its then 250-plus endemic districts, and elimination is judged not by drug delivery alone but by transmission assessment surveys (TAS), with morbidity management — hydrocele surgery, lymphoedema foot care — running alongside for those already damaged.
What you must remember
- Drug regimens: DA — DEC 6 mg/kg plus albendazole 400 mg, single annual dose; IDA — the same plus ivermectin 200 micrograms/kg, introduced after WHO's 2017 recommendation in a phased, district-wise manner.
- MDA exclusions: children under two years, pregnant women, seriously ill persons, and (for ivermectin) young children by age cutoffs — the standard contra-list viva examiners demand.
- Coverage arithmetic: epidemiological coverage must cross roughly 65 per cent to impact transmission, and programmes aim for 85 per cent and above; compliant coverage, not distribution, is scored.
- Parasite and vector to quote: Wuchereria bancrofti causes the overwhelming share (over 99 per cent) of Indian filariasis; Culex quinquefasciatus, the night-biting vector, matches the nocturnal periodicity of microfilariae.
- Stopping rule: MDA rounds continue until antigen or microfilaria prevalence falls below the threshold (about 2 per cent), after which a TAS in school-entry children decides whether MDA can stop and post-MDA surveillance begins.
- Morbidity management: hydrocelectomy camps for men and trained lymphoedema care for limbs — daily washing, elevation, exercises, and treatment of entry lesions — because MDA cannot reverse established lymphoedema.
- Dates: national MDA from 2004; the elimination deadline, repeatedly revised, now sits within the present decade under accelerated plans.
Anatomy of one MDA round
Consider a district preparing its February round. Enumerators update household registers; schools, anganwadis and marketplaces run information campaigns; drug distributors — teachers, ASHAs, volunteers — are trained to deliver the correct tablets, explain side-effects (transient fever or itching as microfilariae die), and record compliance. On the appointed day, dosing is house-to-house or booth-based; a second day mops up absentees. Supervisors then convert issued tablets into compliance figures, because a swallowed dose counts and a merely distributed one does not — the distinction between reported and evaluated coverage is where many districts fail.
The deeper exam point is why mass treatment works at all: adult worms live in lymphatics for years, producing microfilariae that circulate at night awaiting mosquitoes. A single annual dose does not kill adults reliably but slashes microfilaraemia for months, starving the vector of infective material; repeat rounds year after year push transmission below the level at which it sustains itself. IDA strengthens the same logic with deeper, faster microfilarial clearance — hence fewer rounds — while established elephantiasis and hydrocele, the products of dead adult worms and lymphatic damage, remain surgical and self-care problems that no tablet can undo.
How the exam frames it
Theory papers set "MDA programme for filariasis" as a ten-marker; the top-band answer names the drugs with doses, the coverage threshold, the contra-indications, and TAS — four items most candidates supply only two of. The classic confusion is between chemotherapy and control: diethylcarbamazine is also the treatment of individual clinical filariasis, whereas MDA is population prophylaxis with the same drug — dosage purpose differs. Second trap: dating. GPELF began in 2000 globally, India's MDA in 2004, WHO's IDA recommendation in 2017 with Indian phased adoption thereafter — three dates that get cross-wired. Viva boards also like the biology chain: nocturnal microfilaraemia, night-biting Culex, and the historical practice of night blood surveys. Finally, be ready on why India still has endemic districts after two decades: complacency, side-effect rumours, urban migrant mobility, and coverage gaps, not drug failure.
Frequently asked questions
What drugs are given in filariasis MDA?
The traditional annual regimen is DEC 6 mg/kg with albendazole 400 mg; under WHO's 2017 recommendation many districts now use IDA, adding ivermectin 200 micrograms/kg.
Who is excluded from MDA?
Children under two years, pregnant women, the severely ill, and ivermectin-ineligible young children in IDA districts are excluded after screening, and excluded persons are recorded rather than silently skipped.
What coverage makes an MDA round effective?
Epidemiological coverage above roughly 65 per cent is the minimum to interrupt transmission, with programmes targeting 85 per cent or more; compliance, measured by actual consumption, is the indicator that matters.
What is a transmission assessment survey?
TAS tests school-entry children after MDA rounds push infection below threshold, deciding whether mass administration can stop and post-MDA surveillance can begin.
Which parasite and vector dominate Indian filariasis?
Wuchereria bancrofti accounts for over 99 per cent of infections, transmitted mainly by Culex quinquefasciatus, whose night-biting habit matches the nocturnal periodicity of microfilariae.